Physical activity habits in early Parkinson’s disease and healthy controls
Objective: Investigate the physical activity habits of Parkinson’s disease (PD) and healthy control (HC) participants of the PPMI cohort. Background: Exercise can improve the motor…The occurrence of dopamine-responsive and dopamine-resistant resting tremor in Parkinson’s disease
Objective: To investigate dopamine-responsiveness of resting tremor in Parkinson’s disease Background: Unlike the core Parkinson motor symptom, bradykinesia, resting tremor has a variable response to…How to switch from Entacapone to Opicapone based on BIPARK-I study experience
Objective: To clarify how easily can entacapone (ENT) be switched to opicapone (OPC), in levodopa-treated patients with Parkinson’s disease (PD) and motor-fluctuations. Background: OPC, a…Effect of food on Opicapone pharmacokinetics and pharmacodynamics
Objective: To characterize the effect of food on the pharmacokinetics (PK) and pharmacodynamics (PD) of opicapone (OPC) after single and repeated doses. Background: OPC, a…Decision-making process for opicapone’s bedtime regimen
Objective: To clarify the decision-making process for opicapone’s bedtime regímen. Background: OPC, a new once-daily COMT inhibitor, was shown to be effective in the treatment…Levodopa/carbidopa Intestinal Gel Can Improve Both Motor and Non-Motor Experiences of Daily Living in Parkinson’s Disease: An Open-Label Study
Objective: : Our aim was to determine if the MDS-UPDRS and UDysRS could detect improvement in the experiences of daily living following 1-year LCIG treatment.…Towards Responsive Deep Brain Stimulation for Medically Refractory Freezing of Gait in Parkinson’s Disease
Objective: Medically refractory FoG presents an unmet and pressing need to develop novel therapeutic strategies. We seek to describe the electrophysiology of the pedunculopontine nucleus…Tozadenant phase 3 study (TOZ-PD) in Parkinson’s disease patients with motor fluctuations: baseline characteristics
Objective: To describe the baseline characteristics of the TOZ-PD study population. Background: Tozadenant is an adenosine A2A antagonist under investigation as an adjunct to levodopa…Associating patient impression of improvement with efficacy endpoints in Parkinson’s disease: A post-hoc analysis of a tozadenant study
Objective: To evaluate whether patient perceived improvement of Parkinson’s disease (PD) symptoms was associated with improvement in efficacy endpoints (mean daily OFF time and ON…A Phase 3 Study of isradipine as a disease modifying agent in patients with early Parkinson’s disease (STEADY-PD III): Baseline characteristics and study update
Objective: To evaluate the efficacy of isradipine 10 mg daily to slow progression of disability in early PD. Background: Isradipine, a dihydropyridine calcium channel antagonist,…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.